KNTPF (Kintor Pharmaceutical) Net Margin %: -437.59% (As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
20 GF Score
Price $0.34
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Net Margin %?

Kintor Pharmaceutical KNTPF 20 Net Margin % is -437.59% as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Kintor Pharmaceutical ranks worse than 72.88% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Kintor Pharmaceutical's Net Income for the six months ended in Dec. 2025 was $-16.59 Mil. Kintor Pharmaceutical's Revenue for the six months ended in Dec. 2025 was $3.79 Mil. Therefore, Kintor Pharmaceutical's net margin for the quarter that ended in Dec. 2025 was -437.59%.

The historical rank and industry rank for Kintor Pharmaceutical's Net Margin % or its related term are showing as below:

KNTPF' s Net Margin % Range Over the Past 10 Years
Min: -15539.72   Med: -2783.04   Max: -610.77
Current: -610.77

KNTPF's Net Margin % is ranked worse than
72.88% of 944 companies
in the Biotechnology industry
Industry Median: -88.815 vs KNTPF: -610.77

Kintor Pharmaceutical  (OTCPK:KNTPF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Kintor Pharmaceutical Net Margin % Related Terms

Kintor Pharmaceutical Net Margin % Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Net Margin % Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -2,460.22 0.00 0.00 -3,104.66 -612.31

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1,675.40 -1,392.20 -437.59

KNTPF vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Kintor Pharmaceutical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintor Pharmaceutical Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's Net Margin % falls into.


KNTPF
20GF Score
Kintor Pharmaceutical Ltd KNTPF
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kintor Pharmaceutical's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-28.411/4.64
=-612.31 %

Kintor Pharmaceutical's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-16.589/3.791
=-437.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -437.59% mean?
Kintor Pharmaceutical (KNTPF) has a Net Margin % of -437.59% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Kintor Pharmaceutical and its competitors. According to the industry distribution chart, Kintor Pharmaceutical ranks #688 out of 944 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Kintor Pharmaceutical's Net Margin % too high?
Kintor Pharmaceutical's current Net Margin % is -437.59%. Based on the distribution chart, Kintor Pharmaceutical ranks #688 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #688 out of 944 companies for Net Margin %. This places Kintor Pharmaceutical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Net Margin % is -437.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Net Margin % of -437.59%. The current Net Margin % is -437.59%. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Net Margin % is -437.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score

Get the complete analysis for KNTPF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price